Herbert Boyer

Male

White American, born in Derry, a small town in the Laurel Highlands of western Pennsylvania; the specific ancestral background beyond "European American" is not established in the sourced record.

coded.ethnicities is set to the broad "European American" facet bucket at low confidence — no source located specifies a finer national or ancestral origin, and none should be invented.

Not an immigrant-origin family in any documented sense; both his father and grandfather worked for the Pennsylvania Railroad in the same western Pennsylvania region.

not established

Not established directly, though he attended a Catholic college and credited a Benedictine priest, Fr. Joel Lieb, with steering him toward genetics — suggestive but not confirmation of the family's own religious affiliation.

English

His parents' household in Derry remained a documented fallback through his education, since he commuted to college from home; by the time of the Genentech bet in 1976 he held a tenured-track UCSF faculty position, which was itself the real safety net rather than a family home.

He kept his UCSF salary and faculty position throughout — Genentech was built as a side venture on top of, not instead of, a stable academic income; he served concurrently as Genentech vice president and UCSF professor from 1976 to 1991.

not established

Not established in the sourced record.

None documented — the $500 initial investment was borrowed on a credit card, not funded from savings depletion, and his UCSF income continued throughout.

The hardship was chosen. There was a home to go back to if it failed.

The $500-on-a-credit-card founding stake was a calculated, small personal risk taken from an already-secure tenured academic position, not survival hardship. Distinct from the imposed, non-voluntary economics of his childhood in Derry, which drives the hardness score.

Father was a Pennsylvania Railroad brakeman and later conductor, with an eighth-grade education, who left school at thirteen after his own father's death to help support five younger siblings; mother completed high school and married at eighteen.

Neither parent was self-employed.

Father, eighth grade; mother, high school graduate.

not established

Sources document that Boyer's father was the eldest of six and had to support five younger siblings after his own father's death; Herbert Boyer's own sibling count is not established in the sourced record.

No specific parental income push for schooling is documented; he commuted to a nearby college rather than boarding, which kept costs down, and worked jobs including ditch-digging and newspaper delivery as a teenager.

Neither parent actively encouraged college, though neither opposed it; he has described his own motivation — wanting to leave Derry — as the driving force rather than family push.

not established

No moves before adulthood documented beyond the single town of Derry; not established.

not established

Not established.

not established

No military service located in the sourced record.

not established

No modern ZIP-code/mobility-percentile join performed; childhood was in Derry Borough, Westmoreland County, Pennsylvania, a town of roughly 3,000 people.

Public school in Derry, a graduating class of about 32; he played football, basketball, and baseball and was senior class president.

Derry's principal industries were the Pennsylvania Railroad and a Westinghouse manufacturing plant — proximity to stable industrial employment, not to the life sciences field he would eventually enter.

Derry, PA (childhood, commuted to Saint Vincent College nearby) → Pittsburgh, PA (PhD, University of Pittsburgh) → New Haven, CT (Yale postdoctoral fellowship) → San Francisco, CA (UCSF faculty, 1966 onward).

Robert A. Swanson, a young venture capitalist, cold-called Boyer and asked for ten minutes; the meeting ran three hours and produced Genentech.

His UCSF faculty appointment supplied the laboratory, institutional credibility, and research freedom in which the EcoRI and recombinant-DNA work was done.

Credibility, Skill

Robert A. Swanson co-founded Genentech in 1976, supplying business judgment, the initial approach to Kleiner Perkins, and operating leadership as CEO; Stanley N. Cohen of Stanford was the separate scientific collaborator on the underlying recombinant-DNA technique but was not a Genentech co-founder.

30

Computed from birth year 1936 and UCSF faculty appointment in 1966.

10

From 1966 UCSF appointment to the 1976 Genentech founding.

PhD in biochemistry/bacterial genetics, University of Pittsburgh (1963); BS in biology and chemistry, Saint Vincent College (1958).

not established

Not established — no source located on scholarship, assistantship, or family funding for his BS, PhD, or postdoctoral years. coded credentialFunding is coded "self-funded" at medium confidence, inferred from his commuting and part-time-work pattern rather than a documented scholarship or family-funding claim.

Worked jobs including ditch-digging and newspaper delivery as a teenager; commuted to Saint Vincent College from his parents' home rather than boarding, which limited college costs.

Local Catholic commuter college to a state-university PhD program to an Ivy League postdoctoral fellowship to a University of California faculty post — a public/accessible science-credential ladder rather than an elite pipeline from the outset. He was also rejected by medical school before turning to graduate work in bacterial genetics.

A Benedictine priest at Saint Vincent College, Fr. Joel Lieb, is credited with steering Boyer's interest toward genetics research.

Genentech was capitalized in 1976 with $500 each from Boyer and Swanson; Boyer borrowed his $500 on an American Express card.

Kleiner Perkins staged in an initial $100,000 investment, deliberately sized — in Tom Perkins's words — to "last nine months," given the technical risk was still considered "huge."

Kleiner Perkins partner Tom Perkins functioned as an engaged, operator-style early investor — staging capital in tranches tied to scientific milestones rather than writing a single passive check.

Genentech raised institutional venture capital from its founding and went public on Nasdaq on October 14, 1980, opening at $35/share, spiking to $88, and closing at $71. Roche acquired a majority (roughly 60%) stake in 1990 and bought out the remaining shares in 2009 for about $95/share, roughly $46.8 billion in total.

Boyer and his wife Grace directed a portion of their resources into philanthropy: $10 million to Yale School of Medicine (1990) and $1 million to Saint Vincent College for scholarships (1989).

The Cohen-Boyer recombinant-DNA patent was assigned to Stanford (Cohen's institution) and UCSF (Boyer's institution) rather than held personally by the two scientists; licensing revenue over the patent's life totaled roughly a quarter-billion dollars across the two universities, with named inventors entitled to a statutory share under standard university royalty-sharing policy.

The exact dollar amount Boyer personally received from his inventor's share of UCSF's portion of the royalty stream is not established in the sourced record.

Boyer held an economic equity stake and the vice-president title, not a control-preserving share structure; control passed to Roche in stages (majority in 1990, full ownership in 2009), and Boyer retired from both Genentech and UCSF in 1991.

0

Genentech was his only venture; no prior failed company documented.

Self (the $500 credit-card stake) for the founding risk; Kleiner Perkins absorbed the larger capital risk of the venture itself.

39

Computed from birth (July 1936) and Genentech's April 1976 founding.

Pre-Bayh-Dole-Act (1980) era university technology-transfer norms; the Asilomar biosafety guidelines for recombinant-DNA research had only just been adopted (1975); no venture-backed biotechnology industry yet existed — Genentech is widely credited as its first company.

San Francisco Bay Area, California (UCSF; Genentech later headquartered in South San Francisco)

39

15

Genentech founded 1976 to his 1991 retirement as an active operating executive; patent royalties and equity value continued to accrue afterward.

Biotechnology (recombinant DNA / genetic engineering)

not established

No specific, sourced personal net-worth figure was located for Boyer. coded.magnitude (band 4, $100M–$1B) is the author's best-supported estimate, based on: a founder/VP equity stake in Genentech held through its 1980 IPO (opening $35, closing $71) and fifteen years of operation before his 1991 retirement; a named-inventor share of the Cohen-Boyer patent's roughly $255 million in combined Stanford/UCSF licensing revenue; and documented eight-figure philanthropy ($10M to Yale, $1M to Saint Vincent). This is substantially below Genentech's eventual $46.8B acquisition value, which reflects the company's worth, not Boyer's personal stake — the magnitude here is coded from his personal wealth only, per the site's methodology, and should be read as an order-of-magnitude estimate, not a precise figure.

Journalistic estimate

No disclosed-filing or aggregator net-worth figure exists for Boyer; the magnitude band is inferred from the equity, royalty, and philanthropy record described above rather than a single published estimate.

Wealth came from founder/VP equity in Genentech plus a share of Cohen-Boyer patent royalties, not from his UCSF professor's salary, which he retained throughout as his income floor.

Widely credited as a founder of the biotechnology industry; National Medal of Technology (1989), National Medal of Science (1990), Albert Lasker Award (1980), Lemelson-MIT Prize (1996), and the Shaw Prize (2004, shared with Stanley Cohen).

13

From his 1963 PhD to the 1976 Genentech founding.

Uncapped

No regulatory or legal action was taken against Boyer personally. UCSF's Academic Senate did conduct an internal review of the university's recombinant-DNA research program during the 1970s biosafety debate that followed the Asilomar guidelines — a review of the technology's safety practices, not a finding against Boyer's own conduct. Boyer has said he found that review, and the broader public controversy over recombinant-DNA safety, harder to sit through than never winning a Nobel Prize.

Before

The Academic Senate review and Asilomar-era controversy predate Genentech's 1980 IPO.

Incidental

The biosafety review concerned the technology broadly and did not produce the commercial advantage — it was a regulatory-adjacent headwind Genentech's founding survived, not a mechanism that created the outcome.

Legal gray

No violation was found or alleged; coded here only to reflect that recombinant-DNA research operated in a genuinely unregulated, newly-self-governing space before formal biosafety rules existed.

None

Humble, Grateful, Methodical, Collaborative

Drawn from his own on-record reflections in interview ("I am so lucky... and I'm so grateful") and consistent framing across institutional profiles of his collaborative work with Stanley Cohen.

Insiders

After

Broad public recognition followed the 1976 Cohen-Boyer breakthrough becoming known and, more substantially, Genentech's 1980 IPO and subsequent drug approvals.

Asset